https://pipelinereview.com/Theravance-Biopharma-Achieves-50-Enrollment-in-All-Three-Phase-3-Clinical-Studies-of-Revefenacin-TD-4208-for-Treatment-of-Chronic-Obstructive-Pulmonary-Disease-COPD/